These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34699264)

  • 41. Immune response regulation in the tumor microenvironment by hypoxia.
    Labiano S; Palazon A; Melero I
    Semin Oncol; 2015 Jun; 42(3):378-86. PubMed ID: 25965356
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.
    Dai C; Liang S; Sun B; Kang J
    Front Endocrinol (Lausanne); 2020; 11():608422. PubMed ID: 33362722
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Anti-VEGF Treatment Enhances CD8
    de Almeida PE; Mak J; Hernandez G; Jesudason R; Herault A; Javinal V; Borneo J; Kim JM; Walsh KB
    Cancer Immunol Res; 2020 Jun; 8(6):806-818. PubMed ID: 32238381
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models.
    Shi S; Wang R; Chen Y; Song H; Chen L; Huang G
    PLoS One; 2013; 8(6):e65757. PubMed ID: 23799045
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
    Chen Y; Ramjiawan RR; Reiberger T; Ng MR; Hato T; Huang Y; Ochiai H; Kitahara S; Unan EC; Reddy TP; Fan C; Huang P; Bardeesy N; Zhu AX; Jain RK; Duda DG
    Hepatology; 2015 May; 61(5):1591-602. PubMed ID: 25529917
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
    Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
    Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effective combinatorial immunotherapy for castration-resistant prostate cancer.
    Lu X; Horner JW; Paul E; Shang X; Troncoso P; Deng P; Jiang S; Chang Q; Spring DJ; Sharma P; Zebala JA; Maeda DY; Wang YA; DePinho RA
    Nature; 2017 Mar; 543(7647):728-732. PubMed ID: 28321130
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Promise of Targeting Hypoxia to Improve Cancer Immunotherapy: Mirage or Reality?
    Janji B; Chouaib S
    Front Immunol; 2022; 13():880810. PubMed ID: 35795658
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hypoxia Pathway Proteins As Central Mediators of Metabolism in the Tumor Cells and Their Microenvironment.
    Sormendi S; Wielockx B
    Front Immunol; 2018; 9():40. PubMed ID: 29434587
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunity, Hypoxia, and Metabolism-the Ménage à Trois of Cancer: Implications for Immunotherapy.
    Riera-Domingo C; Audigé A; Granja S; Cheng WC; Ho PC; Baltazar F; Stockmann C; Mazzone M
    Physiol Rev; 2020 Jan; 100(1):1-102. PubMed ID: 31414610
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hypoxia as a driver of resistance to immunotherapy.
    Kopecka J; Salaroglio IC; Perez-Ruiz E; Sarmento-Ribeiro AB; Saponara S; De Las Rivas J; Riganti C
    Drug Resist Updat; 2021 Dec; 59():100787. PubMed ID: 34840068
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anticoagulation therapy promotes the tumor immune-microenvironment and potentiates the efficacy of immunotherapy by alleviating hypoxia.
    Choi JU; Lee NK; Seo H; Chung SW; Al-Hilal TA; Park SJ; Kweon S; Min N; Kim SK; Ahn S; Kim UI; Park JW; Kang CY; Kim IS; Kim SY; Kim K; Byun Y
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34341129
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules.
    Zhou G; Sprengers D; Mancham S; Erkens R; Boor PPC; van Beek AA; Doukas M; Noordam L; Campos Carrascosa L; de Ruiter V; van Leeuwen RWF; Polak WG; de Jonge J; Groot Koerkamp B; van Rosmalen B; van Gulik TM; Verheij J; IJzermans JNM; Bruno MJ; Kwekkeboom J
    J Hepatol; 2019 Oct; 71(4):753-762. PubMed ID: 31195061
    [TBL] [Abstract][Full Text] [Related]  

  • 54. ILT4 functions as a potential checkpoint molecule for tumor immunotherapy.
    Gao A; Sun Y; Peng G
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):278-285. PubMed ID: 29649510
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Agonist anti-GITR antibody significantly enhances the therapeutic efficacy of Listeria monocytogenes-based immunotherapy.
    Shrimali R; Ahmad S; Berrong Z; Okoev G; Matevosyan A; Razavi GSE; Petit R; Gupta S; Mkrtichyan M; Khleif SN
    J Immunother Cancer; 2017 Aug; 5(1):64. PubMed ID: 28807056
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME).
    Bretz AC; Parnitzke U; Kronthaler K; Dreker T; Bartz R; Hermann F; Ammendola A; Wulff T; Hamm S
    J Immunother Cancer; 2019 Nov; 7(1):294. PubMed ID: 31703604
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Obstacles for T-lymphocytes in the tumour microenvironment: Therapeutic challenges, advances and opportunities beyond immune checkpoint.
    Verma NK; Wong BHS; Poh ZS; Udayakumar A; Verma R; Goh RKJ; Duggan SP; Shelat VG; Chandy KG; Grigoropoulos NF
    EBioMedicine; 2022 Sep; 83():104216. PubMed ID: 35986950
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nanocarrier-mediated immunogenic chemotherapy for triple negative breast cancer.
    Liu Y; Qiu N; Shen L; Liu Q; Zhang J; Cheng YY; Lee KH; Huang L
    J Control Release; 2020 Jul; 323():431-441. PubMed ID: 32360890
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in mice.
    Smith JP; Wang S; Nadella S; Jablonski SA; Weiner LM
    Cancer Immunol Immunother; 2018 Feb; 67(2):195-207. PubMed ID: 29043413
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Fueling Cancer Immunotherapy With Common Gamma Chain Cytokines.
    Dwyer CJ; Knochelmann HM; Smith AS; Wyatt MM; Rangel Rivera GO; Arhontoulis DC; Bartee E; Li Z; Rubinstein MP; Paulos CM
    Front Immunol; 2019; 10():263. PubMed ID: 30842774
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.